Clinical trials
Phase 1/2 Dermatitis, Atopic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Terminated | 5 |
| Recruiting | 3 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Haus Bioceuticals | 2 |
| Kang Stem Biotech Co., Ltd. | 2 |
| Organon and Co | 2 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2 |
| UCB Biopharma SRL | 2 |
| Akeso | 1 |
| Amorepacific Corporation | 1 |
| Amytrx Therapeutics, Inc. | 1 |
| AnaMar AB | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dermatitis, Atopic | 49 |
| Eczema | 5 |
| Dermatitis | 3 |
| Skin Diseases | 3 |
| Alopecia | 1 |
| Hypersensitivity, Immediate | 1 |
| Immune System Diseases | 1 |
| Lymphoma, T-Cell, Cutaneous | 1 |
| Mycosis Fungoides | 1 |
| Pruritus | 1 |
Trials
Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.